REGN - Regeneron Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Profile Stock analysts Price Targets & Ratings Chart

REGN is currently covered by 25 analysts with an average price target of $892.7. This is a potential downside of $59.7 (-6.27%) from yesterday's end of day stock price of $952.4.

Regeneron Pharmaceuticals's activity chart (see below) currently has 990 price targets and 773 ratings on display. The stock rating distribution of REGN is 64.89% BUY and 35.11% HOLD.

Stock Analyst Price Targets - Review

Analysts' price targets on this stock were met 84.56% of the time, taking 225.86 days on average.

Highest price target for REGN is $1175, Lowest price target is $641, average price target is $892.7.

Most recent stock forecast was given by JOHN NEWMAN from CANACCORD on 02-Nov-2026. First documented stock forecast 01-Jul-2010.

Overview

Regeneron Pharmaceuticals specializes in  products that enable minimally invasive care.

Products

The da Vinci Surgical System is a robotic surgical system that includes:

  • A console where the surgeon sits and controls the instruments and a high-definition 3D camera.

The surgeon uses the console to control the instruments, which are inserted into the patient’s body through small incisions. The system allows for greater precision and control during surgery, resulting in reduced trauma to the patient and faster recovery times.

The Ion endoluminal system enables minimally invasive biopsies in the lung, which can help diagnose lung cancer and other conditions.

Intuitive Surgical also provides a suite of stapling, energy, and core instrumentation for its surgical systems, as well as progressive learning pathways to support the use of its technology. The company offers a complement of services to its customers, including support, installation, repair, and maintenance, to ensure that its products operate efficiently and effectively.

Moreover, Intuitive Surgical has integrated digital capabilities providing connected offerings that streamline performance for hospitals with program-enhancing insights.

History

The company was founded in 1995 and is headquartered in Sunnyvale, California.

Currently out of the existing stock ratings of REGN, 33 are a HOLD (35.11%), 61 are a BUY (64.89%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 03-Nov-2023

$1175

$219.53 (22.98%)

$875

15 days ago
(02-Nov-2026)

35/38 (92.11%)

$247.11 (26.63%)

319

Buy Since 11-Feb-2020

$1100

$144.53 (15.13%)

$995

15 days ago
(02-Nov-2026)

20/25 (80%)

$172.11 (18.55%)

294

Buy Since 08-Mar-2017

$980

$24.53 (2.57%)

$795

15 days ago
(02-Nov-2026)

34/38 (89.47%)

$52.11 (5.62%)

181

Buy Since 13-May-2024

$1075

$119.53 (12.51%)

$875

15 days ago
(02-Nov-2026)

6/9 (66.67%)

$147.11 (15.85%)

142

Hold Since 02-Jun-2025

$913

$-42.47 (-4.44%)

$810

15 days ago
(02-Nov-2026)

37/52 (71.15%)

$-14.89 (-1.60%)

89

Show more analysts

Please expand the browser size to see the chart

What is REGN (Regeneron Pharmaceuticals) average time for price targets to be met?

On average it took 226 days for the stock forecasts to be reached, with an average price target met ratio of 84.56%.

Which analyst most recently updated their price target on REGN (Regeneron Pharmaceuticals)?

John Newman

Which analyst has the most public recommendations on REGN (Regeneron Pharmaceuticals)?

John Newman works at CANACCORD and has 6 price targets and 5 ratings on REGN

Which analyst is the currently most bullish on REGN (Regeneron Pharmaceuticals)?

Colin Bristow with the highest potential upside of $617.1

Which analyst is the currently most reserved on REGN (Regeneron Pharmaceuticals)?

Marc Goodman with the lowest potential downside of -$490.47
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?